key: cord-0848801-eelmsar0
authors: da Fonseca Orcina, Bernardo; Reia, Verônica Caroline Brito; Simão, Andréa Name Colado; Lonni, Audrey Alesandra Stinghen Garcia; Fernandes, Thais Maria Freire; Poleti, Marcelo Lupion; Vilhena, Fabiano Vieira; da Silva Santos, Paulo Sérgio
title: A recommendation of PHTALOX® for preventing infection and progression of COVID-19: a 1-year summarized update of scientific approaches
date: 2022-01-31
journal: GMS Hyg Infect Control
DOI: 10.3205/dgkh000406
sha: bb3c78e80f4392a68e2365efba4217b658c7eac0
doc_id: 848801
cord_uid: eelmsar0

nan

Letter to the editor Dear editor, The role of the oral cavity in the genesis, progression, and dissemination of COVID-19 has been revealed by breakthroughs in SARS-CoV-2 research [1] . As a result, in 2020, our research group presented a recommendation for PHTALOX ® mouthwash for reducing COVID-19 infection and progression [2] . On this occasion, we revealed the first clinical findings in patients with COVID-19 who utilized PHTALOX ® , an antiviral phthalocyanine derivative (APD), in a gargle/rinse mouthwash protocol [3] . We updated the information with new insights on the usage of the APD method since PHTALOX ® was indicated against SARS-CoV-2 (Table 1) . Hence, combined with immunizations, the activity of products containing PHTALOX ® may help prevent patients from transmitting SARS-CoV-2 and thus help prevent others from contracting COVID-19. Following this logic, additional findings from our study group underscore the positive impact of APD. In epidemiological research, the usage of products containing APD reduced virus dissemination and COVID-19 symptoms [4] . In a populationbased study with a sample that used APD, a reduction (p<0.05) in the incidence of COVID-19 was observed compared to a control population without APD exposure [5] . Thus, while vaccines are the most important tool in combating the COVID-19 pandemic, they are not 100% effective in those vaccinated, and even after the initial dose, antibody production takes several days to mature, followed by reinforcement with additional doses [6] , at which point gargle-and-rinse solutions may be an effective option.

As previously indicated, we emphasize how important it is for scientists and governments to evaluate the impact of APD policies in hospitals and the general community on SARS-COV-2 VL, hence reducing the virus's transmission and severity of COVID-19. 

Chertow D; NIH COVID-19 Autopsy Consortium; HCA Oral and Craniofacial Biological NetworkFrank K

A Recommendation of PHTALOX® Mouthwash for Preventing Infection and Progression of COVID-19

The use of antiviral Phthalocyanine mouthwash as a preventive measure against COVID-19

A recommendation of PHTALOX® for preventing infection

Population-based virucidal phthalocyanine gargle/rinse protocol to reduce the risk of coronavirus disease-2019: a community trial

Toothbrushing with a dentifrice containing antimicrobial phthalocyanine derivative for the intraoral reduction of viral load of SARS-CoV-2: a pilot study

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Virucidal Activity of the Antiseptic Mouthwash and Dental Gel Containing Anionic Phthalocyanine Derivative: In vitro Study

A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series

Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial

A recommendation of PHTALOX® for preventing infection and progression of COVID-19: a 1-year summarized update of scientific approaches